Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bispecific CD19/CD20 CAR-T in B-Cell Malignancies
NCT03271515Phase 1Unknown
- Sponsor
- Beijing DOING Biomedical Technology
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Anti-CD19/CD20 bispecific CAR-T in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Beijing DOING Biomedical Technology. Primary endpoint: Antitumor Effects at 24 months. Status: unknown.
02
Drugs
Anti-CD19/CD20 bispecific CAR-T
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03271515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271515.